The American College of Veterinary Internal Medicine (ACVIM) recently issued guidelines that recommend pimobendan (VETMEDIN) be given to dogs as part of standard treatment at the onset of clinical signs of CHF.1
This recommendation reinforces the results of the QUEST* study, which found that VETMEDIN-treated dogs with CHF due to valvular heart disease lived virtually twice as long as those on an ACE inhibitor.2 And by improving the clinical signs of CHF in dogs with atrioventricular valvular insufficiency (AVVI) or dilated cardiomyopathy (DCM), VETMEDIN has been shown to make dogs feel better.2,3
Boehringer Ingelheim Vetmedica, Inc. has launched Quest for Life to help communicate the treatment benefits of using VETMEDIN in accordance with established best clinical practices to hospitals and their clients that have dogs with CHF. It features 2 valuable programs to help you explore your treatment options and drive at-risk dogs into your office.
VETMEDIN should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. The safety of VETMEDIN has not been established in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than atrioventricular valvular insufficiency or dilated cardiomyopathy. Please refer to the Full Prescribing Information here.
*The QUEST study was completed using VETMEDIN Capsules. In the US, only the chewable tablets are licensed. Both the capsules and chewable tablets contain the same pharmaceutical ingredient, pimobendan, and are considered equivalent for clinical use. Bioequivalence, however, has not been shown.
Provides a treatment trial that lets you see how VETMEDIN can help your patients
Helps you communicate with pet owners about the importance of both early diagnosis of heart disease and the recommended treatment protocols for dogs with CHF